Campbell Neurosciences, a spin off company of Therapeutic Solutions International (TSOI), has announced exciting new data, covered by its filed patents, that shows CampbellCell universal donor stem cells have the potential to reduce symptoms of schizophrenia in an animal model.
This is made possible through the stimulation of immune modulation and increased production of the cytokine brain derived neurotrophic factor (BDNF). This is incredibly promising news and could be a major breakthrough in the treatment of schizophrenia.
In a series of groundbreaking experiments, it was discovered that CampbellCell administration had a powerful effect on reducing the development of schizophrenia. Specifically, the administration of CampbellCell resulted in a significant upregulation of the cytokine interleukin-4, which was then able to suppress the inflammatory cytokine interleukin-17 and halt the progression of the illness.
Dr. Thomas Ichim, President and CEO of Campbell Neurosciences, recently announced the impressive progress being made in the development of a biomarker-based test for suicidal ideations. This revolutionary saliva-based detection system will measure inflammatory cytokines, allowing for earlier and more accurate diagnosis.
In addition, the groundbreaking CampbellCell is being developed, a mesenchymal lineage stem cell with the ability to produce neurotrophic factors that can reduce inflammation in the brain, particularly that seen with schizophrenia. This remarkable breakthrough offers hope for improved treatments of these disorders.
Recent studies have revealed the potential for CampbellCell technology to be used in the treatment of schizophrenia, a condition associated with an increased risk of suicide and immunological abnormalities.
This promising treatment has been associated with the modulation of several immune cells, including M2 monocytes and natural killer T cells, and is thought to have a positive effect on reducing brain inflammation. These findings suggest that there may be a potential to use this technology to effectively treat schizophrenia.
Therapeutic Solutions International is proud to celebrate the swift progress of Campbell Neurosciences, the only company utilizing immunotherapy and regenerative medicine to address mental health diagnosis and treatment.
Dr. Ichim’s remarkable contributions have been key to this success, as he is the inventor of over 300 issued and published patent applications. Thanks to the hard work of the team at Campbell Neurosciences, the goal of a world without suicide is closer than ever to becoming a reality.
About Therapeutic Solutions International, Inc.
At Therapeutic Solutions International, we are dedicated to discovering innovative immunotherapies for a range of debilitating diseases. Our cutting-edge research is pioneering the way to more effective treatments and improved patient outcomes.
About Campbell Neurosciences, Inc.
At Campbell Neurosciences, we are dedicated to uncovering the biological roots of suicide and mental health disorders such as Schizophrenia, so that we can help to eradicate the damaging stigma associated with them. By uncovering the biological basis of diagnosis and treatment, we aim to make a real difference in the lives of those affected.